Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

61. Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis

Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis Cahill AG, Odibo AO, Stout MJ, Grobman WA, Macones GA, Caughey AB Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of magnesium treatment, for pregnant women at high risk of delivery before 32 weeks gestation, for the prevention of cerebral palsy in pre-term infants. Based on the evidence available, magnesium

NHS Economic Evaluation Database.2011

62. Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth

Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth Scientific Impact Paper No. 29 August 2011Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth 1. Background The prevalence of preterm birth is increasing. 1 While the survival of infants born preterm has improved, 2 the prevalence of cerebral palsy has risen. 3 The incidence of cerebral palsy decreases significantly with increasing (...) to reduce the effects of this disabling condition on individuals, families, health care and society. 2. Neuroprotection In the late 1990s studies of infants born to mothers given magnesium sulphate to prevent eclamptic seizures or as tocolysis showed a reduction in rates of cystic periventricular leucomalacia (PVL) and cerebral palsy. In those babies born preterm and exposed to magnesium sulphate 8 the odds ratio for cerebralpalsywas0.14(95%CI0.05–0.51). 9 Althoughtheexactmechanismofactionofmagnesium

Royal College of Obstetricians and Gynaecologists2011

63. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study

Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2010

64. Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: A randomized controlled study

Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: A randomized controlled study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2010

65. Efficacy and Tolerability of Split-Dose Magnesium Citrate: Low-Volume (2 Liters) Polyethylene Glycol vs. Single- or Split-Dose Polyethylene Glycol Bowel Preparation for Morning Colonoscopy

Efficacy and Tolerability of Split-Dose Magnesium Citrate: Low-Volume (2 Liters) Polyethylene Glycol vs. Single- or Split-Dose Polyethylene Glycol Bowel Preparation for Morning Colonoscopy 20485282 2010 06 04 2010 07 15 2015 11 19 1572-0241 105 6 2010 Jun The American journal of gastroenterology Am. J. Gastroenterol. Efficacy and tolerability of split-dose magnesium citrate: low-volume (2 liters) polyethylene glycol vs. single- or split-dose polyethylene glycol bowel preparation for morning (...) colonoscopy. 1319-26 10.1038/ajg.2010.79 Preparation regimens for morning colonoscopy are suboptimal. The aim of this study was to test the efficacy and tolerance of a split-dose magnesium citrate-low-volume (2 liters) polyethylene glycol (PEG) regimen for morning colonoscopy. A total of 232 patients were randomly assigned to receive 4 liters PEG (day before procedure; group 1, n=79), 2 liters PEG (day before procedure) followed by another 2 liters PEG (day of procedure; group 2, n=80), or magnesium

EvidenceUpdates2010

66. Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials

Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials Ma L, Liu WG, Zhang JM, Chen G, Fan J, Sheng HS CRD summary This review (...) assessed the effectiveness and safety of intravenous magnesium therapy in patients with aneurysmal subarachnoid haemorrhage and found reduced risks of delayed cerebral ischaemia and poor outcome. This was generally a well-conducted review and the authors’ conclusions reflect the evidence presented but, as acknowledged by the authors, several limitations should be considered when interpreting the results. Authors' objectives To assess the effectiveness and safety of intravenous magnesium therapy

DARE.2010

68. Magnesium Sulfate for Asthma Attack

Magnesium Sulfate for Asthma Attack Magnesium Sulfate for Asthma Attack – TheNNTTheNNT Intravenous Magnesium Sulfate Given During an Asthma Attack 3 for prevented hospital admission In Summary, for those who took the magnesium: Benefits in NNT 67% saw no benefit 33.3% of severe asthmatics were helped by preventing hospital admission 1 in 3 were helped (preventing hospital admission if patient is a "severe asthmatic") None were helped (preventing hospital admission if patient is not a "severe (...) asthmatic") Harms in NNT 0% of severe asthmatics were harmed by serious side effects 100% of non-severe asthmatics were neither helped nor harmed None were harmed (serious side effects, vital sign abnormalities) View As: NNT % Source: Efficacy Endpoints: Hospital admission Harm Endpoints: Tachycardia, tremor Narrative: This review included 7 trials, (N = 665) of which 5 were adult and 2 pediatric. Magnesium sulfate was administered early in the study period, in the first 60 minutes in 5 of the studies

theNNT2010

70. SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, magnesium sulfate) Oral Solution

SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, magnesium sulfate) Oral Solution Drug Approval Package: SUPREP (sodium sulfate, potassium sulfate, magnesium sulfate) NDA #022372 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, magnesium sulfate) Oral Solution Company: Braintree Laboratories, Inc. Application No.: 022372 Approval Date: 08/05/2010 Persons with disabilities having

FDA - Drug Approval Package2010

71. Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets

Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets Company: Pozen Application No.: 022511 Approval Date: 4/30/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2010

72. Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial

Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial 19349375 2009 04 30 2009 05 26 2013 11 21 1098-4275 123 5 2009 May Pediatrics Pediatrics Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial. e764-9 10.1542/peds.2007-3642 The goal was to study whether postnatal magnesium sulfate infusion could improve neurologic outcomes at discharge for term neonates with severe perinatal asphyxia. Forty term (> or =37 weeks of gestation (...) ) neonates with severe perinatal asphyxia were studied in a prospective, longitudinal, placebo-controlled trial. Patients were assigned randomly to receive either 3 doses of magnesium sulfate infusion at 250 mg/kg per dose (1 mL/kg per dose) 24 hours apart (treatment group) or 3 doses of normal saline infusion (1 mL/kg per dose) 24 hours apart (placebo group). Both groups also received supportive care according to the unit protocol for perinatal asphyxia. In the treatment group, moderate encephalopathy

EvidenceUpdates2009

73. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.

Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. BACKGROUND: Epidemiological and basic science evidence suggests that magnesium sulphate before birth may be neuroprotective for the fetus. OBJECTIVES: To assess the effects of magnesium sulphate as a neuroprotective agent when given to women considered at risk of preterm birth. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 August 2008). SELECTION CRITERIA (...) : Randomised controlled trials of antenatal magnesium sulphate therapy in women threatening or likely to give birth at less than 37 weeks' gestational age. For one subgroup analysis, studies were broadly categorised by the primary intent of the study into "neuroprotective intent", or "other intent (maternal neuroprotective - pre-eclampsia)", or "other intent (tocolytic)". DATA COLLECTION AND ANALYSIS: At least two authors assessed trial eligibility and quality, and extracted data. MAIN RESULTS: Five trials

Cochrane2009

74. A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate

A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate Zhao XD, Zhou YT, Zhang X, Zhuang Z, Shi JX CRD summary This review concluded that there was a reduced likelihood of a poor outcome for patients treated with magnesium sulphate following subarachnoid haemorrhage, but that patient mortality was not improved. Given (...) the potential for bias and poor reporting of parts of the review process along with the inclusion of small trials of unknown quality, these findings should be interpreted with caution. Authors' objectives To assess the effectiveness of magnesium sulphate for the prevention of cerebral vasospasm following aneurysmal subarachnoid haemorrhage. Searching EMBASE and PubMed were searched from 1989 to December 2008; search terms were reported. Study selection Randomised controlled trials (RCTs) that investigated

DARE.2009

75. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis

Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis Costantine MM, Weiner SJ, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (...) Network CRD summary This well-conducted review found that foetal exposure to magnesium sulphate in women at risk of preterm delivery significantly reduced the risk of cerebral palsy without increasing the risk of death. These conclusions were supported by the data and are likely to be reliable. Authors' objectives To review the evidence regarding neuroprotective effects of antenatal exposure to magnesium sulphate and to explore the findings at different gestational ages. Searching PubMed and Cochrane

DARE.2009

76. Magnesium sulphate effective neuroprotection for the foetus of women at risk of preterm delivery

Magnesium sulphate effective neuroprotection for the foetus of women at risk of preterm delivery

Cochrane PEARLS2009

77. Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants

Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants Article Text Therapeutics Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants Statistics from Altmetric.com No Altmetric data available for this article. Question In women at risk of preterm delivery, does magnesium sulphate provide

Evidence-Based Medicine (Requires free registration)2009

78. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis

Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis Conde-Agudelo A, Romero R CRD summary (...) This well-conducted review concluded that magnesium sulphate administered to women at risk of delivery before 34 weeks of gestation reduced the risk of cerebral palsy in their children. The authors' conclusions are likely to be reliable. Authors' objectives To determine the efficacy and safety of antenatal magnesium sulphate administered to women at risk of pre-term delivery before 34 weeks of gestational age for the prevention of cerebral palsy in their children. Searching PubMed, EMBASE, CINAHL

DARE.2009

79. The Efficacy of Administration of Intravenous Magnesium Sulfate for Improved Ventricular Rate Control or Rhythm Control in Patients with Non-postoperative Atrial Fibrillation and Atrial Flutter

The Efficacy of Administration of Intravenous Magnesium Sulfate for Improved Ventricular Rate Control or Rhythm Control in Patients with Non-postoperative Atrial Fibrillation and Atrial Flutter "The Efficacy of Administration of Intravenous Magnesium Sulfate for Im" by Mary Schindeler < > > > > > Title Author Date of Award 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers MS, PA-C Second Advisor Rob Rosenow (...) PharmD, OD Rights . Abstract INTRODUCTION: Standard treatment for atrial tachyarrthmias, such as atrial fibrillation or atrial flutter, involves rate and rhythm control. Previous studies have looked at the electrophysiologic effects of magnesium on impulse formation and propagation, and theorized it could be beneficial in treatment for atrial tachycardias. There recently have been studies about magnesium sulfate and its utility in establishing rate and rhythm control in patients

Pacific University EBM Capstone Project2009

80. Magnesium for acute traumatic brain injury.

Magnesium for acute traumatic brain injury. BACKGROUND: Acute traumatic brain injury is a leading cause of death and disability in young adults. Numerous pharmacological and non-pharmacological tools have been investigated and considered as potential mechanisms for improving neurological outcome. Magnesium has been considered as one of these potential therapeutic tools because of its activity on NMDA-receptors, calcium channels and neuron membranes. Animal studies have indicated a beneficial (...) effect of magnesium on outcome after brain injury, but its efficacy in humans is unknown. OBJECTIVES: To quantify the effect of magnesium administration on mortality and morbidity in patients with acute traumatic brain injury. SEARCH STRATEGY: We searched the Cochrane Injuries Group's specialised register, Cochrane Central Register of Controlled Trials, CENTRAL (The Cochrane Library issue 2, 2008), MEDLINE (and PubMed to 28 May, 2008: last 60 days), EMBASE, National Research Register, Current

Cochrane2008